Dexmedetomidine HCL Injection + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Awake Fiberoptic Intubation
Conditions
Awake Fiberoptic Intubation
Trial Timeline
Aug 1, 2006 → Mar 1, 2007
NCT ID
NCT00383890About Dexmedetomidine HCL Injection + Placebo
Dexmedetomidine HCL Injection + Placebo is a phase 3 stage product being developed by Pfizer for Awake Fiberoptic Intubation. The current trial status is completed. This product is registered under clinical trial identifier NCT00383890. Target conditions include Awake Fiberoptic Intubation.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00383890 | Phase 3 | Completed |